Today, we launched our FY26 full-year results. FY26 was a year of transition and setting a path to return to sustainable growth. To learn more about our results and how we’ve simplified the business and invested in our commercial capabilities, visit our Investor Centre: investors.csl.com/ #CSL

Today, we broke ground on a $1.5 billion investment to expand our plasma manufacturing capacity in Kankakee, Illinois. Read how this will support the production of plasma-derived therapies and create new jobs in the US: newsroom.csl.com/2026-03-09-… #CSL #PlasmaDerivedTherapies #RareDisease

Today we announced our half‑year results. Read the full ASX announcement for details: bit.ly/4tzf89M #CSL

Today we’ve announced that Gordon Naylor has been appointed interim Chief Executive Officer and Managing Director, following Dr Paul McKenzie’s decision to retire. Read more: bit.ly/46DKj9K

Today, we announced an upcoming $1.5b in future U.S. capital investments, further strengthening our contribution to the U.S. healthcare ecosystem. This expansion builds on our significant U.S. presence and over $3b invested since 2018. This investment will generate hundreds of high-quality American jobs and substantially bolster U.S. manufacturing for critical plasma-derived therapies. Our goal is to meet the growing clinical need for these life-saving medicines, which are often the sole effective treatments for many rare and serious diseases. We are proud to continue investing in American innovation and talent. newsroom.csl.com/2025-11-18-… #CSL #USManufacturing #PlasmaDerivedTherapies #HealthcareInnovation #AmericanJobs

October is #PlasmaAwarenessMonth, an opportunity to thank our plasma donors for their generosity and to bring awareness of the important role that plasma plays in helping patients. Our plasma-derived therapies are made possible by the donation of plasma, and these therapies are used to help treat certain serious and rare conditions, including immune deficiencies and bleeding disorders. In certain medical situations, plasma-derived products may also be used in trauma care and maternal health. We encourage everyone to learn more about the #PowerofPlasma, to share the message, and consider becoming a donor themselves. Learn more here: csl.com/we-are-csl/our-busin… #CSLPlasma #PlasmaAwarenessMonth #DonatePlasma

Today we shared our full-year results for FY25. Take a look at some of the key financial and operational highlights. For more details visit our Investor Centre: investors.csl.com/ #CSL #FullYearResults

Applications for the 2026 CSL Centenary Fellowships will close on 30 June. We are inviting Australia’s top early-mid career scientists to apply for next year’s fellowships now. bit.ly/466kBez

Innovation meets convenience with our first homegrown mAb to gain approval, offering a new option that may help patients manage their condition. We’re proud to bring this innovation to the HAE community. bit.ly/4jZZuOH

The U.S. FDA has approved the only once-monthly treatment targeting factor XIIa to prevent attacks of HAE. This reflects our commitment to HAE patients around the world, a community we have proudly supported for over four decades. Read more: bit.ly/3FFkoEI.